Intuitive Surgical stock steadies as da Vinci 5 cardiac clearance reshapes growth story
Published on 08/19/2026 at 09:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Intuitive Surgical Inc. (US46120E6023) stock has fallen more than 30 percent year to date in 2026, but recent data as of August 18, 2026 show the shares stabilizing in the high-$390 to low-$400 range on the Nasdaq as investors weigh robust procedure growth against tempered guidance and rising competition. A recent second-quarter earnings overview covering the period through June 30, 2026 reported 16 percent worldwide procedure growth and 19 percent revenue growth, underscoring that the underlying robotic-surgery business remains firmly in expansion mode even as the stock price reflects a reset in expectations.
A separate market commentary dated August 18, 2026 highlights that Intuitive Surgical stock is on track for its weakest calendar-year performance since 2008, with the shares down around 30 percent so far in 2026 despite double-digit growth in da Vinci procedure volumes and continued adoption across hospitals and surgical specialties. That same analysis cites recent closes between $390.24 and $394.51 as of August 17 and August 18, 2026, a level that is more than 30 percent below early-2026 prices above $560 and illustrates how valuation has compressed sharply while operational metrics continue to climb.
2026 share performance and latest price levels
Per detailed market data compiled on August 18, 2026, Intuitive Surgical stock closed at $391.18 on August 18, 2026 at 4:00 p.m. ET, with a modest gain of 0.22 percent on the day and a small uptick to $391.50 in extended trading that same evening. The quote snapshot situates that closing level within a broader recent trading band reported between roughly $390.24 and $394.51 in mid-August 2026, pointing to contained day-to-day volatility around a new, lower plateau for the shares.
Additional price and valuation context from a comprehensive quote page shows Intuitive Surgical stock trading with a one-year price range from $254.85 to $496.48, meaning the latest high-$390 quote sits well below the 52-week high and reflects a pullback of more than $100 from the top end of that range. The same data set reports a market capitalization of $171.263 billion and a trailing price-to-earnings ratio of 82.67 based on earnings per share of $5.83, underscoring that even after the 2026 drawdown Intuitive Surgical still commands a premium valuation relative to many medtech peers.
Looking at an alternative real-time quote source updated on August 19, 2026, Intuitive Surgical shares are reported at $391.54 as of the close on August 18, 2026, up 0.31 percent for the session, with a market cap of roughly $138.57 billion and a trailing EPS figure of 8.36. The same overview indicates a forward average analyst target price of $480.77 and a consensus rating of Buy, highlighting that despite the recent volatility, the sell-side community still sees upside relative to the current trading level while acknowledging the risks implied by the lower guidance range.
Earnings, guidance and procedure growth in Q2 2026
In mid-July 2026, Intuitive Surgical reported second-quarter earnings for the period ended June 30, 2026, providing investors with a detailed look at how the robotic-surgery franchise is performing in the face of macro uncertainty and competitive pressure. The earnings recap notes that worldwide procedure growth in the quarter reached 16 percent, while total revenue increased 19 percent year over year, indicating that hospitals are continuing to ramp up da Vinci usage and that the installed base is generating more recurring instrument and accessories revenue.
Despite those double-digit growth figures, the same coverage explains that investors reacted cautiously to management's full-year guidance for da Vinci procedure growth, which was set in a range of 13.5 percent to 15.5 percent for 2026. Putting the guidance in perspective, the midpoint of 14.5 percent represents a moderation compared with the 16 percent growth already achieved in the second quarter, effectively signaling that management expects some deceleration in procedure momentum over the back half of 2026. For investors, the delta between the 16 percent realized growth in Q2 and the 13.5 to 15.5 percent guided range for the full year is a clear quantified comparison that helps explain why the stock has derated even as operating trends remain robust.
Another portfolio commentary dated August 18, 2026 reinforces that the second-quarter numbers were modestly ahead of consensus expectations but that valuation and competitive concerns weighed on the share price. That portfolio letter reports da Vinci procedure growth of 16 percent in the quarter, consistent with the broader earnings recap, and notes that Intuitive Surgical's forward price-to-earnings multiple has been cut roughly in half since late January 2026 amid a broad sell-off in medtech and worries about emerging competition in soft tissue robotics and instrumentation.
From a valuation standpoint, a separate strategic analysis published on August 18, 2026 points out that Intuitive Surgical trades at a forward price-to-earnings ratio of 10.88, which is above the industry average but significantly lower than its own five-year median forward multiple of 15.78. The same discussion observes that the consensus estimate for Intuitive Surgical's 2026 earnings implies 20.3 percent growth compared with the prior year's level, illustrating that analysts still expect meaningful profit expansion even though the stock's valuation has compressed relative to its historical norms.
Da Vinci 5 and expanding cardiac indications
Beyond the numbers, a key recent operational catalyst for Intuitive Surgical has been expanded regulatory clearance for cardiac surgery using its newest platform, the da Vinci 5 system. A detailed regulatory and product update explains that Intuitive Surgical has received clearance to perform several cardiac procedures on da Vinci 5 using non-force-feedback instruments, opening a new category of robot-assisted interventions in cardiology across markets where the system is approved.
The same update quantifies the opportunity by noting that in 2025, around 17,000 cardiac procedures were performed globally using earlier-generation da Vinci systems such as Si and Xi, establishing a baseline for existing robotic cardiac usage. Intuitive Surgical's own estimates cited in that analysis suggest that in markets where da Vinci 5 is now cleared, including the United States and South Korea, the immediate annual opportunity is 160,000 cardiac procedures per year. Comparing those figures implies a potential expansion by more than ninefold relative to the 2025 observed volume of 17,000 cardiac procedures, a scale that could materially influence long-term growth trajectories if adoption in cardiac surgery ramps in line with that opportunity.
Separate clinical news from a major regional health system highlights how da Vinci technology is already pushing into more complex thoracic procedures. An announcement from ECU Health describes how a cardiothoracic surgeon there performed North Carolina's first single-port robotic upper lung lobectomies using the da Vinci SP system, with the initial right upper lobectomy completed on May 19, 2026 and the first left upper lobectomy performed on June 15, 2026. Those dates provide concrete evidence that hospitals are moving beyond more routine soft tissue procedures into advanced lung operations using Intuitive Surgical's single-port technology.
In another example of clinical expansion, a feature story on robotic heart surgery notes that El Camino Health in Silicon Valley has begun performing robotic-assisted coronary artery bypass grafting using the da Vinci 5 robotic surgical system. The same report emphasizes that this approach can reduce recovery time, pain and hospital stays for eligible patients compared with traditional open-heart surgery that requires cutting through the breastbone. For investors, such evidence of real-world adoption in high-acuity cardiac procedures underscores how the new cardiac indications for da Vinci 5 may translate into tangible procedure growth and deeper clinical integration over time.
Software, valuation and competitive dynamics
As robotic platforms become more sophisticated, software is emerging as a critical differentiator, and recent analysis positions Intuitive Surgical's software strategy as increasingly important alongside its hardware. The valuation-focused article argues that while Intuitive Surgical may not appear cheap compared with the broader industry on traditional metrics, its investments in software, digital tools and data analytics could support improved utilization, procedure efficiency and surgeon experience, potentially justifying a higher multiple if those capabilities deepen its moat.
Within that same assessment, the consensus projection of 20.3 percent earnings growth in 2026 versus the prior year is juxtaposed against the reduced forward valuation, with the forward price-to-earnings ratio at 10.88 relative to a five-year median of 15.78. The combination of a lower multiple and still-healthy expected profit growth suggests that the market has repriced the stock more on sentiment and risk than on a collapse in fundamentals, leaving room for rerating if Intuitive Surgical demonstrates sustained growth and effective response to emerging competition.
Portfolio commentary from an institutional strategy further underlines the impact of sector-wide medtech weakness on Intuitive Surgical's share price. The strategy letter notes that Intuitive Surgical's forward price-to-earnings multiple has been cut in half since late January 2026, linked to both a broad sell-off in medical device and medtech names and to concerns over possible competition in soft tissue robotics and surgical instruments. For shareholders, that numeric halving of the forward multiple is a key quantified comparison against the stock's prior valuation and helps explain why the 30 percent year-to-date price decline has occurred despite double-digit growth in procedures and revenue.
At the same time, the letter outlines that Intuitive Surgical remained a meaningful position within the portfolio in the second quarter, with an average weight of 2.64 percent and a total portfolio return contribution of negative 0.40 percentage points, reflecting that while the stock detracted from performance it remained a core holding based on its long-term growth thesis. For investors following the name, such details indicate that professional managers are balancing near-term volatility against structural drivers like demographic trends, surgical migration toward minimally invasive approaches and the deep installed base of da Vinci systems.
Representative product: da Vinci 5 and SureForm stapling
To understand what sits behind Intuitive Surgical's numbers, it helps to look at a specific product combination that is central to its offering. One representative pairing is the da Vinci 5 surgical system together with the company's SureForm stapling portfolio, which bring advanced stapling capabilities into complex minimally invasive procedures. The official SureForm product page explains that SureForm staplers are integrated with da Vinci 5, as well as the da Vinci X, Xi and SP systems, allowing surgeons to control positioning, clamping and firing directly from the console during robotic procedures.
The same product documentation describes various SureForm staplers, including SureForm 45 and SureForm 60, which are designed for resection, transection and the creation of anastomoses in general, thoracic, gynecologic, urologic and pediatric surgeries. It also details the 8 mm SureForm 30 Curved-Tip Stapler and associated reloads, intended for resection and transection of vasculature and tissue while maintaining precise control within confined anatomical spaces. By integrating these stapling tools into the da Vinci ecosystem, Intuitive Surgical enhances the range of procedures that can be performed robotically and deepens the instrument revenue streams tied to each surgical case.
The da Vinci 5 system itself is described as assisting in the accurate control of endoscopes and instruments during minimally invasive endoscopic urologic, gynecologic, general laparoscopic and thoracoscopic surgical procedures, for both adult and pediatric patients. The system carries a European CE mark as a class IIb medical device under the EU Medical Devices Regulation, reflecting its regulatory clearance in that region. For investors, the breadth of indications and the integration of advanced stapling solutions help explain the sustained double-digit procedure growth seen in the second quarter of 2026 and the sizable opportunity described for cardiac applications.
Closing view: price context and investor takeaway
As of August 18, 2026, Intuitive Surgical stock closed at $391.18 on the Nasdaq, with extended trading quotes showing $391.50 later that evening, placing the shares roughly 30 percent below their early-2026 level above $560 and well under the 52-week high of $496.48 even as second-quarter 2026 procedures grew 16 percent and revenue climbed 19 percent year over year. For investors, that combination of compressed valuation, moderated but still double-digit guidance for full-year procedure growth of 13.5 to 15.5 percent, and expanding indications for da Vinci 5 in cardiac surgery frames a nuanced risk-reward profile in which fundamental expansion continues but sentiment and competition have reset expectations.
Fact box
Company: Intuitive Surgical Inc.
ISIN: US46120E6023
Ticker: ISRG
Exchange: Nasdaq
Price (as of August 18, 2026, 4:00 p.m. ET): $391.18 USD
Market cap: $171.263 billion (as of August 18, 2026)
Sector / Industry: Health care equipment - robotic-assisted surgery
Index membership: S&P 500
